Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACACA (ACC1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | ACACA Full-Length Recombinant Protein (HEK293 expressed, biotinylated, >95% purity, endotoxin <1 EU/µg, sequence verified). Also available: catalytic domain construct. | View ACACA Products |
| Antigen (Mutant Panel) | ACACA drug resistance mutant panel covering key catalytic domain variants (e.g., mutations identified in dbSNP and cancer samples) for mechanism-of-resistance studies. High purity (>95%). | View ACACA Products |
| Detection / Benchmark Antibody | Anti-ACACA recombinant rabbit monoclonal antibody suitable for Western blot, IP, IF; also available as control antibody for assay normalization. | View ACACA Products |
| Gene Delivery | ACACA Promise-ORF / Lentivirus premade particles (full-length ORF, codon-optimized) for stable cell line construction in lipogenesis assays. | View ACACA Products |
| Validator (siRNA) | ACACA siRNA set (3 target-specific + 1 negative control) for knockdown verification, off-target analysis, and target engagement validation. | View ACACA Products |
| Isoform Counter-Screen | ACACB (ACC2) recombinant protein and antibody panel – critical for metabolic safety and isoform selectivity profiling. | View ACACB Products |
| Pathway Partner 1 | FASN (Fatty Acid Synthase) recombinant protein – downstream lipogenic enzyme; synergy and resistance bypass analysis. | View FASN Products |
| Pathway Partner 2 | ACLY (ATP-Citrate Lyase) recombinant protein – upstream enzyme controlling citrate flux into acetyl-CoA. | View ACLY Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ACACA vs ACACB) | Matched human ACACA and ACACB ortholog pair with >95% purity, sequence verified by mass spec; enables accurate SPR / BLI selectivity ratios. |
| Cross-Species Metabolic Translation | Human, mouse, and cynomolgus ortholog proteins available; theoretical MW confirmed, endotoxin controlled (<1 EU/µg). |
| Large Multi-Domain Structure Expression | Rationally designed functional domain constructs (BC and CT domains) with sequence and MW verification; full-length protein also available. |
| Drug Resistance Screening | Mutant ACACA panel with sequence-verified alleles (e.g., catalytic domain hot-spots) for studying acquired resistance mechanisms. |
| Intracellular Target Engagement | ACACA siRNA and Lentivirus for stable knockdown/overexpression in HepG2 or Huh7 lipogenesis models; benchmark antibody included for readout. |
| Assay Specificity / False Positives | Endotoxin-controlled proteins (<1 EU/µg); validated siRNA as cellular specificity control; high-purity reagents minimize off-target enzymatic noise. |
Live ACACA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACACA (ACC1) therapeutics is intensifying. Historically driven by broad dual ACC1/ACC2 allosteric inhibitors for NASH/MASH, the field has experienced setbacks due to metabolic compensation (hypertriglyceridemia, muscle-related adverse events) from the first generation of molecules such as Gilead/Nimbus's firsocostat and Pfizer's PF-05175157. The next wave of R&D is pivoting toward isoform-selective small molecules, liver-targeted delivery (siRNA/GalNAc conjugates, antisense oligonucleotides), and targeted protein degradation (PROTACs). Oncology indications—particularly hepatocellular carcinoma, breast cancer, and non-small cell lung cancer—are now a major focus because lipogenic tumors rely on ACACA-dependent de novo lipogenesis for biomass accumulation. Future differentiation will depend on achieving high ACACA/ACACB selectivity (>100-fold) to preserve peripheral fatty acid oxidation, combining with immunotherapy or upstream pathway inhibitors (e.g., ACLY, FASN), and proactively addressing resistance through mutant protein panels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Gilead/Nimbus (firsocostat legacy), Pfizer, Merck, Bayer, Nimbus Therapeutics | NASH/MASH, Hepatocellular Carcinoma, Obesity, Type 2 Diabetes | Enzymatic inhibition assay – requires high-purity biotinylated ACACA holoenzyme and ACACB for selectivity IC50 comparison. |
| siRNA / GalNAc Conjugate / Antisense | Ionis, Arrowhead, emerging RNAi platforms | NASH, Dyslipidemia, NAFLD | Cell-based knockdown validation – need ACACA siRNA and ORF lentivirus for rescue experiments. |
| PROTAC / Degrader | Arvinas, academic labs | Refractory solid tumors | Degradation kinetics – require stable cell lines (lentivirus), benchmark antibodies, and ACACA/ACACB proteins for selectivity readout. |
| Combination Therapy | Gilead (w/ FXR agonist), academic consortia | Advanced fibrosis, MASH, Breast cancer | Pathway counter-screening – need FASN, ACLY, AMPK pathway proteins for synergy studies. |
中文深度分析（中文洞察）
全球研发格局
ACACA（乙酰辅酶A羧化酶1，又称ACC1）是脂肪酸从头合成（de novo lipogenesis, DNL）的限速酶，在肝脏、脂肪组织及多种实体瘤中高度表达。当前全球研发格局呈现显著变化：代谢性疾病（NASH/MASH）方向遇冷——第一代双靶点（ACC1/ACC2）抑制剂如Gilead的firsocostat和Pfizer的PF-05175157相继因高甘油三酯血症、肌肉毒性等代谢代偿问题而终止或收缩；肿瘤学方向迅速升温——肝细胞癌、乳腺癌、非小细胞肺癌等脂成瘾（lipogenesis addiction）肿瘤成为新的主战场。代表企业包括Nimbus Therapeutics（ND-646等结构设计分子）、Bayer（专利布局）、Ionis（ASO策略）。模态分布上：小分子占约85%（其中大部分从双靶点转向选择性抑制），核酸药物约10%，PROTAC等降解技术约5%。
前瞻性市场预测（未来3-5年）
- 异构体选择性成为临床硬指标：ACACA（胞质）与ACACB（线粒体）同源性约75%，但功能迥异。完全抑制ACACB会导致心肌和骨骼肌脂肪酸氧化紊乱。预计未来First-in-class分子必须具备ACACA/ACACB >100倍的体外选择性窗口。
- 组织特异性递送破解安全瓶颈：通过GalNAc偶联、前药设计或肝脏靶向LNP，可将抑制剂精确递送至肝脏，减少全身暴露。这将是慢性代谢疾病长期用药的关键。
- 耐药性问题提前布局：随着临床推进，ACACA催化结构域（尤其CT结构域）的变构位点突变将导致获得性耐药。已有研究预示I1163F（基于同源建模）等热点突变。临床前阶段应建立耐药突变蛋白面板进行筛选。
- PROTAC带来全新机遇：传统小分子难以解决ACC1的脚手架功能（scaffolding function）。利用PROTAC彻底降解ACC1蛋白，可能在难治性肿瘤中提供更深度的疾病控制。
分子差异化与Assay策略
- 异构体选择性筛选：必须使用同一表达体系（如HEK293）生产的ACACA与ACACB全长或功能域蛋白，并行测定IC50，消除批次差异。TarMart提供序列验证、内毒素控制的同源蛋白对。
- 酶活性保持与翻译后修饰：ACACA为生物素依赖酶，需要真核表达系统保证正确折叠和生物素化。E. coli表达产物往往失活。TarMart的全长蛋白经SDS-PAGE和质谱确认理论分子量（~265 kDa）。
- 耐药突变筛查：针对CT结构域的变构抑制剂易产生耐药。利用点突变蛋白面板（如基于结构生物学热点预测的突变体）进行shift assay，指导二代药物设计。
- 靶点占用率验证：对于肝脏靶向分子，需要构建稳定细胞系（慢病毒）和siRNA敲低对照，在细胞水平确认靶点占有率与药效关系。TarMart提供完整的ORF慢病毒及siRNA套装。
关联靶点推荐
- ACACB（ACC2）：必备的异构体对照，任何ACACA项目必须考虑选择性。
- FASN：下游直接底物利用酶，ACACA+FASN双抑制在肿瘤中可能产生合成致死。
- ACLY：上游乙酰辅酶A提供者，ACLY抑制剂与ACACA抑制剂在NASH中可产生通路协同。
- SCD1：平行脂合成关键酶，共享SREBP-1c调控，双重抑制可能更有效降低脂毒性。
- AMPK：ACACA的上游负调控激酶，磷酸化失活ACACA；作为机制验证对照靶点。
综上，针对ACACA项目的研发者应构建“通路面板”概念，不满足于单靶点抑制，而应同时评估ACACA、ACACB、FASN、ACLY等关键节点，以应对适应性耐药并实现真正的临床差异化。